Auggmin Lifesciences. Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth -22.16%
- Profit Growth 103.20%
- Ebitda 130.55%
- Net Worth 3.35%
- Total Assets 54.33%
About Auggmin Lifesciences.
Auggmin Lifesciences. Private Limited (ALPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 October 2017 (Seven years and four months 24 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Akhil Chadha and Raman Aggarwal serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999DL2017PTC324408
- Company No.
324408
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Oct 2017
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Auggmin Lifesciences. Private Limited offer?
Auggmin Lifesciences. Private Limited offers a wide range of products and services, including Tea & Coffee, Coffee Beans.
Who are the key members and board of directors at Auggmin Lifesciences.?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akhil Chadha  | Director | 03-Oct-2017 | Current |
| Raman Aggarwal | Director | 25-Oct-2017 | Current |
Financial Performance of Auggmin Lifesciences..
Auggmin Lifesciences. Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 22.16% decrease. The company also saw a substantial improvement in profitability, with a 103.2% increase in profit. The company's net worth moved up by a moderate rise of 3.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Auggmin Lifesciences.?
In 2018, Auggmin Lifesciences. had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Robotics Logistics Private LimitedAkhil Chadha and Raman Aggarwal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Auggmin Lifesciences.?
Unlock and access historical data on people associated with Auggmin Lifesciences., such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Auggmin Lifesciences., offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Auggmin Lifesciences.'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
